Cargando…

The Safety, Tolerability, and Efficacy of Once-Daily Memantine (28 mg): A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial in Patients with Moderate-to-Severe Alzheimer’s Disease Taking Cholinesterase Inhibitors

INTRODUCTION: Immediate-release memantine (10 mg, twice daily) is approved in the USA for moderate-to-severe Alzheimer’s disease (AD). This study evaluated the efficacy, safety, and tolerability of a higher-dose, once-daily, extended-release formulation in patients with moderate-to-severe AD concurr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Grossberg, George T., Manes, Facundo, Allegri, Ricardo F., Gutiérrez-Robledo, Luis Miguel, Gloger, Sergio, Xie, Lei, Jia, X. Daniel, Pejović, Vojislav, Miller, Michael L., Perhach, James L., Graham, Stephen M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2013
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3680656/ https://www.ncbi.nlm.nih.gov/pubmed/23733403 http://dx.doi.org/10.1007/s40263-013-0077-7

Ejemplares similares

Memantine combined with an acetyl cholinesterase inhibitor – hope for the future?
por: Fox, Chris, et al.
Publicado: (2006)

Memantine and Cholinesterase Inhibitors: Complementary Mechanisms in the Treatment of Alzheimer’s Disease
por: Parsons, Chris G., et al.
Publicado: (2013)

Persistent treatment with cholinesterase inhibitors and/or memantine slows clinical progression of Alzheimer disease
por: Rountree, Susan D, et al.
Publicado: (2009)

Memantine and cholinesterase inhibitor combination therapy for Alzheimer's disease: a systematic review
por: Farrimond, Lucy E, et al.
Publicado: (2012)

Memantine ER Maintains Patient Response in Moderate to Severe Alzheimer’s Disease: Post Hoc Analyses From a Randomized, Controlled, Clinical Trial of Patients Treated With Cholinesterase Inhibitors
por: Grossberg, George T., et al.
Publicado: (2018)

The effects of lumiracoxib 100 mg once daily vs. ibuprofen 600 mg three times daily on the blood pressure profiles of hypertensive osteoarthritis patients taking different classes of antihypertensive agents
por: MacDonald, T M, et al.
Publicado: (2010)

Efficacy and Safety of Terbinafine 500 mg Once Daily in Patients with Dermatophytosis
por: Babu, P Ravindra, et al.
Publicado: (2017)

Combination Therapy with Cholinesterase Inhibitors and Memantine for Alzheimer’s Disease: A Systematic Review and Meta-Analysis
por: Matsunaga, Shinji, et al.
Publicado: (2015)

Cholinesterase inhibitors and memantine for Parkinson's disease dementia and Lewy body dementia: A meta-analysis
por: Meng, Yan-Hong, et al.
Publicado: (2019)

Long-term retention on treatment with lumiracoxib 100 mg once or twice daily compared with celecoxib 200 mg once daily: A randomised controlled trial in patients with osteoarthritis
por: Fleischmann, Roy, et al.
Publicado: (2008)

Systematic Review and Meta-Analysis of Combination Therapy with Cholinesterase Inhibitors and Memantine in Alzheimer's Disease and Other Dementias
por: Muayqil, Taim, et al.
Publicado: (2012)

Cumulative, additive benefits of memantine-donepezil combination over component monotherapies in moderate to severe Alzheimer’s dementia: a pooled area under the curve analysis
por: Atri, Alireza, et al.
Publicado: (2015)

Duloxetine 60 mg once daily in the treatment of milder major depressive disorder
por: Perahia, DGS, et al.
Publicado: (2006)

Association of Concomitant Use of Cholinesterase Inhibitors or Memantine With Cognitive Decline in Alzheimer Clinical Trials: A Meta-analysis
por: Kennedy, Richard E., et al.
Publicado: (2018)

Memantine: a review of studies into its safety and efficacy in treating Alzheimer’s disease and other dementias
por: Thomas, Stuart J, et al.
Publicado: (2009)

A Real-world Analysis of Treatment Patterns for Cholinesterase Inhibitors and Memantine among Newly-diagnosed Alzheimer’s Disease Patients
por: Bent-Ennakhil, Nawal, et al.
Publicado: (2017)

A fixed-dose combination of memantine extended-release and donepezil in the treatment of moderate-to-severe Alzheimer’s disease
por: Deardorff, William James, et al.
Publicado: (2016)

Clinical Acceptability Of Trimetazidine Modified-Release 80 mg Once Daily Versus Trimetazidine Modified-Release 35 mg Twice Daily In Stable Angina Pectoris
por: Pozdnyakov, Yuri M.
Publicado: (2018)

Comparative safety and effectiveness of cholinesterase inhibitors and memantine for Alzheimer’s disease: a network meta-analysis of 41 randomized controlled trials
por: Dou, Kai-Xin, et al.
Publicado: (2018)

Once-daily dosing of gentamicin.
por: Soper, D E
Publicado: (1998)

Important Error in ‘Systematic Review and Meta-Analysis of Combination Therapy with Cholinesterase Inhibitors and Memantine in Alzheimer's Disease and Other Dementias’ by Muayqil and Camicioli
por: Tariot, Pierre N., et al.
Publicado: (2014)

Comparative Value of Cholinesterase Inhibitors and Memantine in Persons with Moderate-to-Severe Alzheimer’s Disease in the United States: A Cost-Effectiveness Analysis(1)
por: Yunusa, Ismaeel, et al.
Publicado: (2021)

Erratum to: Comparative Value of Cholinesterase Inhibitors and Memantine in Persons with Moderate-to-Severe Alzheimer’s Disease in the United States: A Cost-Effectiveness Analysis
Publicado: (2021)

A Novel Once-Daily Fixed-Dose Combination of Memantine Extended Release and Donepezil for the Treatment of Moderate to Severe Alzheimer’s Disease: Two Phase I Studies in Healthy Volunteers
por: Boinpally, Ramesh, et al.
Publicado: (2015)

Safety and Efficacy of Memantine in Children with Autism: Randomized, Placebo-Controlled Study and Open-Label Extension
por: Aman, Michael G., et al.
Publicado: (2017)

Medical therapy options for aging men with benign prostatic hyperplasia: focus on alfuzosin 10 mg once daily
por: Roehrborn, Claus G, et al.
Publicado: (2008)

Review of Efficacy and Safety of Duloxetine 40 to 60 mg Once Daily in Patients with Diabetic Peripheral Neuropathic Pain
por: Skljarevski, Vladimir, et al.
Publicado: (2012)

Efficacy and safety of duloxetine 60 mg once daily in major depressive disorder: a review with expert commentary
por: Ball, Susan G, et al.
Publicado: (2013)

Once-daily 5 mg tadalafil oral treatment for patients with chronic prostatitis/chronic pelvic pain syndrome
por: Benelli, Andrea, et al.
Publicado: (2018)

ONCE DAILY RISPERIDONE IN TREATMENT OF SCHIZOPHRENIA
por: Agarwal, Vivek, et al.
Publicado: (2001)

A population pharmacokinetics analysis assessing the exposure of raltegravir once‐daily 1200 mg in pregnant women living with HIV
por: Bukkems, Vera E., et al.
Publicado: (2021)

Efficacy of Once Daily versus Divided Daily Administration of Low Daily Dosage (15 mg/Day) of Methimazole in the Induction of Euthyroidism in Graves' Hyperthyroidism: A Randomized Controlled Study
por: Sriussadaporn, Sutin, et al.
Publicado: (2017)

Pharmacokinetic and Pharmacodynamic Comparison of Once‐Daily Efavirenz (400 mg vs. 600 mg) in Treatment‐Naïve HIV‐Infected Patients: Results of the ENCORE1 Study
por: Dickinson, L, et al.
Publicado: (2015)

Effect of QT Prolongation in Patients Taking Cholinesterase Inhibitors (Donepezil) for Alzheimer’s Disease
por: Kuwahata, So, et al.
Publicado: (2021)

Comparison of Once-Daily Bromfenac 0.07% Versus Once-Daily Nepafenac 0.3% in Patients Undergoing Phacoemulsification
por: Toyos, Melissa M.
Publicado: (2019)

Benefits of once-daily therapies in the treatment of hypertension
por: Flack, John M, et al.
Publicado: (2011)

ONCE DAILY LITHIUM IN THE PROPHYLAXIS OF MOOD DISORDERS
por: Mohan, Rajesh, et al.
Publicado: (1996)

Efficacy and safety of telithromycin 800 mg once daily for 7 days in community-acquired pneumonia: an open-label, multicenter study
por: Fogarty, Charles M, et al.
Publicado: (2005)

Efficacy and Safety of Tadalafil 5 mg Administered Once Daily in Korean Men with Erectile Dysfunction: A Prospective, Multicenter Study
por: Kang, Dong Hyuk, et al.
Publicado: (2010)

An observational study to monitor the efficacy and tolerability of levofloxacin 500 mg once daily for treatment of chronic bacterial prostatitis in Saudi Arabia
por: El Meliegy, Amr Ismail, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_hn07r5iq9ov0ujiqdam1hk832d